Implant Sciences declared that its QS-B220 Explosives and Narcotics Trace Detector has achieved the certification readiness testing successfully with the Transportation Security Laboratory (TSL).
TSL is Transportation Security Administration’s (TSA) testing division. The B220 is the process of final independent validation testing for TSA qualification supporting air cargo screening.
According to Implant Sciences' President and CEO, Glenn D. Bolduc, the company has achieved a significant milestone as its B220 system has successfully passed the certification readiness testing and has moved into final validation testing with the TSL. Entry into final phase of approval promotes the desktop B220 explosives trace detection system to be ideal for deployment in the global markets and the U.S. While the final stage of testing will take place in the next few weeks, the high performance of the system will enable the company to ensure its shareholders with the system by the end of fiscal Q1, ending September 30, 2012. This will promote investment on the December 3, 2012 date for the air cargo industry to meet the requirements of air cargo screening regulations.
Launched in May 2011, the Ion Mobility Spectrometry (IMS)-based QS-B220 is a desktop explosives and narcotics trace detector that can be effectively deployed for rapid detection of trace amounts of extensive commercial, military, and homemade explosives, as well as narcotic substances. The QS-B220 does not contain radioactive materials, and provides high operational availability and low total cost of ownership.